Skip to main content

Table 3 Overall survival in the total entire population and subgroups

From: Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

   

Overall survival

 
 

Number

Median (months)

 
 

A

B

A

B

P value

 

All patients

58

36

20.2

11.9

0.001

 

Age 69

38

20

19.7

12.9

0.061

NS

  >70

20

16

20.4

8.6

0.001

 

Sex: male

36

20

20.4

6.3

0.001

 

Sex: female

22

16

19.8

12.6

0.094

NS

T1–2

11

9

36.6

20.5

0.086

NS

T3–4

47

27

15.6

9.4

0.000

 

N0

27

15

21.3

13.0

0.007

 

N1

31

21

13.6

7.0

0.017

 

R0

43

28

20.7

12.5

0.001

 

R1

15

8

13.4

5.5

0.034

 

Stage 0–IIA

29

13

23.7

15.4

0.008

 

Stage IIB–IV

29

23

13.4

7.0

0.043

 
  1. NS no significant difference.